Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurotech InternationalNTILF 34 EV-to-OCF is -4.34 as of Aug. 18, 2026. GuruFocus rates NTILF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, Neurotech International ranks better than 58.2% on this metric.
The historical rank and industry rank for Neurotech International's EV-to-OCF or its related term are showing as below:
NTILF'
s EV-to-OCF Range Over the Past 10 Years
Min: -27.22 Med: -5.5 Max: 0.53
Current: -5.48
During the past 9 years, the highest EV-to-OCF of Neurotech International was 0.53. The lowest was -27.22. And the median was -5.50.
NTILF's EV-to-OCF is ranked better than 58.2% of 1409
companies
in the Biotechnology industry
Industry Median: -3.6
vs NTILF: -5.48
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neurotech International (OTCPK:NTILF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Neurotech International's PE Ratio (TTM) for today is calculated as:
Neurotech International's share price for today is $0.001.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neurotech International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Neurotech International's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurotech International EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neurotech International's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Neurotech International's EV-to-OCF falls into.
Neurotech International's current Enterprise Value is $8.39 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neurotech International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurotech International (NTILF) has a EV-to-OCF of -4.34 as of Aug. 18, 2026. According to the industry distribution chart, Neurotech International ranks #589 out of 1409 companies in the Biotechnology industry, placing it in the top 41.8%.
Is Neurotech International's EV-to-OCF too high?
Neurotech International's current EV-to-OCF is -4.34. Based on the distribution chart, Neurotech International ranks #589 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Neurotech International has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Neurotech International's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurotech International ranks #589 out of 1409 companies for EV-to-OCF. This puts Neurotech International in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Neurotech International's current EV-to-OCF is -4.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (NTILF) has a current EV-to-OCF of -4.34. The current EV-to-OCF is -4.34. Neurotech International's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Neurotech International (NTILF), the current EV-to-OCF is -4.34 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
34GF Score
Get the complete analysis for NTILF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTILF has been successfully added to your 
